Search Results - "Fukuta, Yasuhiko"

Real-world effectiveness and safety of tolvaptan in liver cirrhosis patients with hepatic edema: results from a post-marketing surveillance study (START study) by Sakaida, Isao, Terai, Shuji, Kurosaki, Masayuki, Okada, Mitsuru, Hirano, Takahiro, Fukuta, Yasuhiko

“…Background This large-scale post-marketing surveillance study (START study) evaluated the effectiveness and safety of tolvaptan in Japanese liver cirrhosis…”
Get full text

Real-World Effectiveness and Tolerability of Tolvaptan in Patients With Heart Failure　― Final Results of the Samsca Post-Marketing Surveillance in Heart Failure (SMILE) Study by Kinugawa, Koichiro, Sato, Naoki, Inomata, Takayuki, Yasuda, Moriyoshi, Shimakawa, Toshiyuki, Fukuta, Yasuhiko

“…Background:In Japan, tolvaptan is indicated for patients with heart failure and volume overload who have inadequate response to other diuretics. In contrast to…”
Get full text

Real-world effectiveness and safety of aripiprazole augmentation therapy in patients with major depressive disorder by Kamijima, Kunitoshi, Yasuda, Moriyoshi, Yamamura, Kayo, Fukuta, Yasuhiko

“…Aims: Augmentation therapy is an option for patients with major depressive disorder who do respond sufficiently to adequate dosages of selective serotonin…”
Get full text

Effectiveness and safety of tolvaptan in liver cirrhosis patients with edema: Interim results of post‐marketing surveillance of tolvaptan in liver cirrhosis (START study) by Sakaida, Isao, Terai, Shuji, Kurosaki, Masayuki, Yasuda, Moriyoshi, Okada, Mitsuru, Bando, Kosuke, Fukuta, Yasuhiko

“…Aim Loop diuretics and spironolactone are used in patients with hepatic edema, but they are sometimes associated with insufficient responses as well as adverse…”
Get full text

Aripiprazole in the real-world treatment for irritability associated with autism spectrum disorder in children and adolescents in Japan: 52-week post-marketing surveillance by Sugimoto, Yuna, Yamamura, Kayo, Takayama, Tomoyo, Fukuta, Yasuhiko, Aoki, Kazuo, Mikami, Katsunaka, Tomoda, Akemi

“…The purpose of this study was to evaluate the post-marketing safety and effectiveness of aripiprazole in treating irritability in pediatric patients (6-17…”
Get full text

A Prospective, Multicenter, Post-Marketing Surveillance Study to Evaluate the Safety and Effectiveness of Tolvaptan in Patients with Reduced, Preserved, and Mid-Range Ejection Fraction Heart Failure by Kinugawa, Koichiro, Sato, Naoki, Inomata, Takayuki, Yasuda, Moriyoshi, Shimakawa, Toshiyuki, Fukuta, Yasuhiko

“…Tolvaptan, a vasopressin V2 receptor antagonist, is approved in Japan for the treatment of fluid retention in patients with heart failure (HF), and in the…”
Get full text

Who Needs Longer Tolvaptan Treatment?: An Interim Analysis From the Samsca post-Marketing surveillance In heart faiLurE (SMILE study) by Kinugawa, Koichiro, Inomata, Takayuki, Sato, Naoki, Yasuda, Moriyoshi, Shimakawa, Toshiyuki, Bando, Kosuke, Fukuta, Yasuhiko

“…The vasopressin receptor 2 (V2) receptor antagonist tolvaptan is an aquaretic agent that has been approved for heart failure patients with volume overload in…”
Get full text

Who Needs Longer Tolvaptan Treatment? by Kinugawa, Koichiro, Inomata, Takayuki, Sato, Naoki, Yasuda, Moriyoshi, Shimakawa, Toshiyuki, Bando, Kosuke, Fukuta, Yasuhiko

“…The vasopressin receptor 2 (V2) receptor antagonist tolvaptan is an aquaretic agent that has been approved for heart failure patients with volume overload in…”
Get full text

The Real-World Outcomes of Ponatinib in 724 Patients with CML and Ph + ALL : A Post-Marketing Surveillance Study with a Special Interest in Arterial Occlusive Events in Japan by Takahashi, Naoto, Kondo, Takeshi, Ikari, Yuji, Fukumoto, Yoshihiro, Hatake, Kiyohiko, Masunari, Akira, Nishibayashi, Seiji, Kageyama, Akiko, Fukuta, Yasuhiko, Tojo, Arinobu

“…Introduction Ponatinib inhibits the BCR::ABL1 kinase, including a variant with threonine-to-isoleucine at position 315 (T315I) (Cortes et al. N Eng J Med…”
Get full text

Real-world safety and effectiveness of rotigotine in patients with Parkinson's disease: analysis of a post-marketing surveillance study in Japan by Ito, Hidefumi, Takayama, Tomoyo, Kondo, Hiroyuki, Fukuta, Yasuhiko

“…The aim of this study was to evaluate the safety and effectiveness of rotigotine under daily clinical practice in Parkinson's disease patients. The study was a…”
Get full text

Real-world outcomes of ponatinib treatment in 724 patients with CML and Ph+ ALL: a post-marketing surveillance study with a special interest in arterial occlusive events in Japan by Takahashi, Naoto, Kondo, Takeshi, Ikari, Yuji, Fukumoto, Yoshihiro, Hatake, Kiyohiko, Masunari, Akira, Nishibayashi, Seiji, Kageyama, Akiko, Fukuta, Yasuhiko, Tojo, Arinobu

“…Abstract Background In September 2016, ponatinib was approved in Japan for the treatment of patients with chronic myeloid leukemia with resistance/intolerance…”
Get full text

Real-World Effectiveness and Tolerability of Tolvaptan in Patients With Heart Failure　― Final Results of the Samsca Post-Marketing Surveillance in Heart Failure (SMILE) Study by Kinugawa, Koichiro, Sato, Naoki, Inomata, Takayuki, Yasuda, Moriyoshi, Shimakawa, Toshiyuki, Fukuta, Yasuhiko

“…Background:In Japan, tolvaptan is indicated for patients with heart failure and volume overload who have inadequate response to other diuretics. In contrast to…”
Get full text

Comparison of glucose and fat as energy sources in peripheral parenteral nutrition in rats by Fukuta, Y. (Nippon Hoechst Marion Roussel Ltd., Yasu, Shiga (Japan)), Arii, K, Matsuda, A, Kokuba, Y

“…Glucose is usually chosen as the energy source for total parenteral nutrition. However the optimal glucose: fat ratio for peripheral parenteral nutrition has…”
Get full text

Correlation between intravenously supplied energy level and zinc metabolism in laparotomized rats by Fukuta, Y. (Nippon Hoechst Marion Roussel Ltd., Yasu, Shiga (Japan)), Isegawa, J, Matsuda, A, Kokuba, Y

“…We investigated the relationship between intravenous energy loading and zinc status in laparotomized rats. One of three test solutions consisting of 3% amino…”
Get full text

Who Needs Longer Tolvaptan Treatment? by Kinugawa, Koichiro, Inomata, Takayuki, Sato, Naoki, Yasuda, Moriyoshi, Shimakawa, Toshiyuki, Bando, Kosuke, Fukuta, Yasuhiko

“…The vasopressin receptor 2 (V2) receptor antagonist tolvaptan is an aquaretic agent that has been approved for heart failure patients with volume overload in…”
Get more information

Preparation of fine emulsified fat particles without glycerol for intravenous nutrition by Arii, Kanji, Fukuta, Yasuhiko, Kai, Toshiya, Kokuba, Yukifumi

“…A method of preparing fine emulsified fat particles without glycerol for intravenous nutrition was investigated. The factors assessed were the oil phase ratio,…”
Get full text

The effect of alpha-linolenic acid-rich emulsion on fatty acid metabolism and leukotriene generation of the colon in a rat model with inflammatory bowel disease by Inui, K, Fukuta, Y, Ikeda, A, Kameda, H, Kokuba, Y, Sato, M

“…The purpose of this study was to investigate the efficacy of alpha-linolenic acid-rich perilla oil emulsion (POE) in a rat model with trinitrobenzenesulfonic…”
Get more information

The nutritional effect of a-linolenic acid-rich emulsion with total parenteral nutrition in a rat model with inflammatory bowel disease by Inui, K, Fukuta, Y, Ikeda, A, Kameda, H, Kokuba, Y, Sato, M

“…The purpose of this study was to investigate the nutritional effect of perilla oil emulsion (POE) in a rat model with inflammatory bowel disease (IBD) induced…”
Get more information